P4 Diagnostix®

Mammogen Touts Growing List of 2021 Awards and Recognitions for its Work in Women’s Health and Breast Cancer Diagnostics

Retrieved on: 
Thursday, October 28, 2021
Women, Other Health, Consumer, Health, Oncology, Woman, RNA transfection, Breast cancer, GA, Efficiency, Diagnosis, Technology, Blood, Industry, Informatics, Association, Pathology, CLIA, Partnership, Saliva, RNA, American Association for Clinical Chemistry, Time, Life, CEO, P4, Survivor, American Association, AACC, Medical imaging, Mammogen, P4 Diagnostix®, Brilliantly, MAMMOGEN, P4 DIAGNOSTIX®, BRILLIANTLY

Mammogen, a female-led womens health company, today has announced a list of 2021 awards and recognitions for its work in womens health and, more specifically, breast cancer.

Key Points: 
  • Mammogen, a female-led womens health company, today has announced a list of 2021 awards and recognitions for its work in womens health and, more specifically, breast cancer.
  • Mammogen selected as one of two womens health companies featured throughout the 2021 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Atlanta, GA
    The awards and recognitions come off the heels of two recent partnership announcements.
  • The companys flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.
  • Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, General Health, Other Health, Health, Oncology, Blood, Efficiency, Explainable artificial intelligence, Non-alcoholic fatty liver disease, Saliva, Entrepreneurship, EHR, Â, Pathology, Informatics, Laboratory, Liquid biopsy, Breast cancer, Industry, Classification, Lung, NAFL, Behavior, Health, IV, NAFLD, IP, NASH, CEO, Disease, Science, Technology, Lists of diseases, Fatty liver disease, Clinical trial, Partnership, Molecular medicine, Solution, Woman, Risk, Liver, Agnostic (data), R, Ecosystem, Intellectual property, Time, LBS, Degenerative disease, Diagnosis, CLIA, Patient, Biology, Lung cancer, Research, Drug development, Data analysis, Time-invariant system, Medical imaging, Fine chemical, Medical device, IV BioHoldings, P4 Diagnostix®, Liquid Biosciences, IV BIOHOLDINGS, P4 DIAGNOSTIX®, LIQUID BIOSCIENCES

Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

Key Points: 
  • Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.
  • IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization.
  • We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.